Medscinet U.K. Ltd - Period Ending 2019-04-30

Medscinet U.K. Ltd - Period Ending 2019-04-30


Medscinet U.K. Ltd 05948933 false 2018-05-01 2019-04-30 2019-04-30 The principal activity of the company is the provision of internet based medical applications Digita Accounts Production Advanced 6.21.8540.0 Software true 05948933 2018-05-01 2019-04-30 05948933 2019-04-30 05948933 bus:OrdinaryShareClass1 2019-04-30 05948933 core:RetainedEarningsAccumulatedLosses 2019-04-30 05948933 core:ShareCapital 2019-04-30 05948933 core:CurrentFinancialInstruments core:WithinOneYear 2019-04-30 05948933 core:FurnitureFittingsToolsEquipment 2019-04-30 05948933 bus:SmallEntities 2018-05-01 2019-04-30 05948933 bus:AuditExemptWithAccountantsReport 2018-05-01 2019-04-30 05948933 bus:AbridgedAccounts 2018-05-01 2019-04-30 05948933 bus:SmallCompaniesRegimeForAccounts 2018-05-01 2019-04-30 05948933 bus:RegisteredOffice 2018-05-01 2019-04-30 05948933 bus:CompanySecretary1 2018-05-01 2019-04-30 05948933 bus:Director1 2018-05-01 2019-04-30 05948933 bus:OrdinaryShareClass1 2018-05-01 2019-04-30 05948933 bus:PrivateLimitedCompanyLtd 2018-05-01 2019-04-30 05948933 bus:Agent1 2018-05-01 2019-04-30 05948933 core:FurnitureFittings 2018-05-01 2019-04-30 05948933 core:FurnitureFittingsToolsEquipment 2018-05-01 2019-04-30 05948933 core:KeyManagementPersonnelCloseFamilyMembersEntitiesUnderKeyManagementPersonnelsControl 2018-05-01 2019-04-30 05948933 core:ParentEntities 2018-05-01 2019-04-30 05948933 countries:UnitedKingdom 2018-05-01 2019-04-30 05948933 2018-04-30 05948933 core:FurnitureFittingsToolsEquipment 2018-04-30 05948933 2017-05-01 2018-04-30 05948933 2018-04-30 05948933 bus:OrdinaryShareClass1 2018-04-30 05948933 core:RetainedEarningsAccumulatedLosses 2018-04-30 05948933 core:ShareCapital 2018-04-30 05948933 core:CurrentFinancialInstruments core:WithinOneYear 2018-04-30 05948933 core:FurnitureFittingsToolsEquipment 2018-04-30 iso4217:GBP xbrli:pure xbrli:shares

Registration number: 05948933

Medscinet U.K. Ltd

Filleted Annual Report and Unaudited Abridged Financial Statements

for the Year Ended 30 April 2019

HSJ Accountants Ltd
Severn House
Hazell Drive
Newport
South Wales
NP10 8FY

 

Medscinet U.K. Ltd

Contents

Company Information

1

Accountants' Report

2

Abridged Balance Sheet

3 to 4

Notes to the Abridged Financial Statements

5 to 8

 

Medscinet U.K. Ltd

Company Information




 

Director

Mr Magnus Westgren

Company secretary

Mr Marius Kublickas

Registered office

Dept of Womens Health
10th Floor, North Wing
St. Thomas Hospital
London
SE1 7EH

Accountants

HSJ Accountants Ltd
Severn House
Hazell Drive
Newport
South Wales
NP10 8FY

 

Accountants' Report to the Director on the Preparation of the Unaudited Statutory Accounts of
Medscinet U.K. Ltd
for the Year Ended 30 April 2019

As described on the balance sheet you are responsible for the compilation of the accounts for the year ended 30 April 2019, as set out on pages 3 to 8, and you consider that the company is exempt from an audit. In accordance with your instructions we have compiled the unaudited accounts from the accounting records and from information and explanations supplied to us.














HSJ Accountants Ltd
Severn House
Hazell Drive
Newport
South Wales
NP10 8FY

23 May 2019

 

Medscinet U.K. Ltd

(Registration number: 05948933)
Abridged Balance Sheet as at 30 April 2019

Note

2019
£

2018
£

Fixed assets

 

Tangible assets

4

4,354

5,361

Current assets

 

Debtors

54,389

78,894

Cash at bank and in hand

 

343,784

394,530

 

398,173

473,424

Prepayments and accrued income

 

1,516

1,657

Creditors: Amounts falling due within one year

(17,471)

(40,013)

Net current assets

 

382,218

435,068

Total assets less current liabilities

 

386,572

440,429

Accruals and deferred income

 

(116,520)

(136,226)

Net assets

 

270,052

304,203

Capital and reserves

 

Called up share capital

5

1,000

1,000

Profit and loss account

269,052

303,203

Total equity

 

270,052

304,203

 

Medscinet U.K. Ltd

(Registration number: 05948933)
Abridged Balance Sheet as at 30 April 2019

For the financial year ending 30 April 2019 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Director's responsibilities:

The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476; and

The director acknowledges his responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These financial statements have been prepared in accordance with the special provisions relating to companies subject to the small companies regime within Part 15 of the Companies Act 2006.

These financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime and the option not to file the Profit and Loss Account has been taken.

All of the company’s members have consented to the preparation of an Abridged Balance Sheet in accordance with Section 444(2A) of the Companies Act 2006.

Approved and authorised by the director on 23 May 2019
 

.........................................

Mr Magnus Westgren
Director

 

Medscinet U.K. Ltd

Notes to the Abridged Financial Statements for the Year Ended 30 April 2019

1

General information

The company is a private company limited by share capital, incorporated in United Kingdom.

The company registration number is: 05948933

The address of its registered office is:
Dept of Womens Health
10th Floor, North Wing
St. Thomas Hospital
London
SE1 7EH

These financial statements were authorised for issue by the director on 23 May 2019.

2

Accounting policies

Summary of significant accounting policies and key accounting estimates

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

Statement of compliance

These abridged financial statements were prepared in accordance with Financial Reporting Standard 102 section 1A 'The Financial Reporting Standard applicable in the UK and Republic of Ireland'.

Basis of preparation

These abridged financial statements have been prepared using the historical cost convention except that as disclosed in the accounting policies certain items are shown at fair value.

Tax

The tax expense for the period comprises current tax. Tax is recognised in profit or loss, except that a change attributable to an item of income or expense recognised as other comprehensive income is also recognised directly in other comprehensive income.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the reporting date in the countries where the company operates and generates taxable income.

Tangible assets

Tangible assets are stated in the statement of financial position at cost, less any subsequent accumulated depreciation and subsequent accumulated impairment losses.

The cost of tangible assets includes directly attributable incremental costs incurred in their acquisition and installation.

Depreciation

Depreciation is charged so as to write off the cost of assets, other than land and properties under construction over their estimated useful lives, as follows:

Asset class

Depreciation method and rate

Furniture, fittings and equipment

15% Straight line

 

Medscinet U.K. Ltd

Notes to the Abridged Financial Statements for the Year Ended 30 April 2019

Cash and cash equivalents

Cash and cash equivalents comprise cash on hand and call deposits, and other short-term highly liquid investments that are readily convertible to a known amount of cash and are subject to an insignificant risk of change in value.

Trade debtors

Trade debtors are amounts due from customers for merchandise sold or services performed in the ordinary course of business.

Trade debtors are recognised initially at the transaction price. They are subsequently measured at amortised cost using the effective interest method, less provision for impairment. A provision for the impairment of trade debtors is established when there is objective evidence that the company will not be able to collect all amounts due according to the original terms of the receivables.

Trade creditors

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Accounts payable are classified as current liabilities if the company does not have an unconditional right, at the end of the reporting period, to defer settlement of the creditor for at least twelve months after the reporting date. If there is an unconditional right to defer settlement for at least twelve months after the reporting date, they are presented as non-current liabilities.

Trade creditors are recognised initially at the transaction price and subsequently measured at amortised cost using the effective interest method.

Borrowings

Interest-bearing borrowings are initially recorded at fair value, net of transaction costs. Interest-bearing borrowings are subsequently carried at amortised cost, with the difference between the proceeds, net of transaction costs, and the amount due on redemption being recognised as a charge to the Profit and Loss Account over the period of the relevant borrowing.

Interest expense is recognised on the basis of the effective interest method and is included in interest payable and similar charges.

Borrowings are classified as current liabilities unless the company has an unconditional right to defer settlement of the liability for at least twelve months after the reporting date.

Share capital

Ordinary shares are classified as equity. Equity instruments are measured at the fair value of the cash or other resources received or receivable, net of the direct costs of issuing the equity instruments. If payment is deferred and the time value of money is material, the initial measurement is on a present value basis.

Dividends

Dividend distribution to the company’s shareholders is recognised as a liability in the financial statements in the reporting period in which the dividends are declared.

 

Medscinet U.K. Ltd

Notes to the Abridged Financial Statements for the Year Ended 30 April 2019

Defined contribution pension obligation

A defined contribution plan is a pension plan under which fixed contributions are paid into a pension fund and the company has no legal or constructive obligation to pay further contributions even if the fund does not hold sufficient assets to pay all employees the benefits relating to employee service in the current and prior periods.

Contributions to defined contribution plans are recognised as employee benefit expense when they are due. If contribution payments exceed the contribution due for service, the excess is recognised as a prepayment.

3

Staff numbers

The average number of persons employed by the company (including the director) during the year, was 2 (2018 - 3).

4

Tangible assets

Furniture, fittings and equipment
 £

Total
£

Cost or valuation

At 1 May 2018

6,709

6,709

At 30 April 2019

6,709

6,709

Depreciation

At 1 May 2018

1,348

1,348

Charge for the year

1,007

1,007

At 30 April 2019

2,355

2,355

Carrying amount

At 30 April 2019

4,354

4,354

At 30 April 2018

5,361

5,361

5

Share capital

Allotted, called up and fully paid shares

 

2019

2018

 

No.

£

No.

£

Ordinary of £1 each

1,000

1,000

1,000

1,000

         
 

Medscinet U.K. Ltd

Notes to the Abridged Financial Statements for the Year Ended 30 April 2019

6

Dividends

Interim dividends paid

   

2019
£

 

2018
£

Interim dividend of Nil (2018 - 20.00) per each Ordinary

 

-

 

20,000

         

7

Related party transactions

Summary of transactions with key management

During the year the company made unsecured, interest free, repayable on demand loans to the director. At the balance sheet the amount due to the company was £523 (2018 - £523).
 

Summary of transactions with parent

MedSciNet AB
 During the year MedSciNet U.K. Ltd paid dividends to its parent company MedSciNet AB totalling £nil (2018 - £20,000). MedSciNet AB charged MedSciNet U.K. Ltd £260,000 (2018 - £60,000) for running UK computer applications and a virtual server.